Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia

Federico Pozzo; Gabriela Forestieri; Filippo Vit; Giulia Ianna; Erika Tissino; Tamara Bittolo; Robel Papotti; Annalisa Gaglio; Lodovico Terzi di Bergamo; Agostino Steffan; Jerry Polesel; Pietro Bulian; Roberta Laureana; Agostino Tafuri; Annalisa Chiarenza; Francesco Di Raimondo; Jacopo Olivieri; Francesco Zaja; Luca Laurenti; Maria Ilaria Del Principe; Massimiliano Postorino; Giovanni Del Poeta; Riccardo Bomben; Antonella Zucchetto; Francesca Maria Rossi; Valter Gattei

doi:10.1038/s41375-024-02301-y

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib represents an effective strategy for treatment of chronic lymphocytic leukemia (CLL), nevertheless about 30% of patients eventually undergo disease progression. Here we investigated by flow cytometry the long-term modulation of the CLL CXCR4

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pozzo et al. (2024) studied this question.

synapsesocial.com/papers/68e637f1b6db6435875c974d https://doi.org/10.1038/s41375-024-02301-y

View Full Paper

Ask AI

Bookmark

Share

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia

Ask about this paper

Abstract

Discussion

Cite This Study

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading